RedHill Biopharma Ltd. (NASDAQ: RDHL) today announced positive top-line safety and efficacy results from the first Phase III study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

RedHill Biopharma (RDHL) Highlights Positive Top-Line Results from Phase III Study of RHB-104 in Crohn's DiseaseAugust 1, 2018 8:17 AM Redhill Biopharma (RDHL) PT Raised to $28 at Nomura/InstinetJuly 30, 2018 1:00 PM RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s DiseaseJuly 30, 2018 7:00 AM